Breaking news · Updated 10-29-2026

Peptide Compounding in 2026: What the HHS Enforcement Discretion Means for Telehealth Founders

By the GrowPro team, led by Jessica Lynne White, PT · Published 10-29-2026 · growpro.co

Short answer: On 10-28-2026, HHS announced temporary enforcement discretion for six peptides (BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax), meaning licensed compounding pharmacies can make them while the FDA finishes formal rulemaking. For telehealth founders it opens a prescribed, pharmacy-filled path for these six, but it is temporary, it is not FDA approval, and the marketing rules do not loosen.

What HHS actually announced

On Wednesday, October 28, 2026, the U.S. Department of Health and Human Services announced temporary enforcement discretion for six peptides: BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. In plain terms, the FDA will not take action against licensed compounding pharmacies that make these six while it completes formal rulemaking on whether to add them to the list of bulk drug substances pharmacies may use. Pharmacies that compound them are expected to certify the identity and purity of what they make and to report side effects. The notice was reported as scheduled for publication in the Federal Register on Friday, October 30, 2026. The six had been reviewed by the FDA's Pharmacy Compounding Advisory Committee, which voted in July 2026 to recommend adding them to the bulks list. A seventh peptide reviewed at that meeting, DSIP, did not get that recommendation.

What enforcement discretion means, in plain English

Enforcement discretion is a decision not to enforce a rule, not a change to the rule itself. The underlying law has not changed, and these six peptides are not FDA-approved drugs. What changed is that regulators have said they will not act against licensed pharmacies compounding them for now. That "for now" matters. Enforcement discretion can be narrowed or withdrawn, and the final rule could land differently than the advisory committee recommended.

What it opens up for telehealth founders

For the first time in this cycle, there is a clear, prescribed path for these six peptides: a licensed provider evaluates the patient, decides whether a prescription is appropriate, and a licensed compounding pharmacy prepares and ships it. That is the same structure every legitimate telehealth category runs on. It also gives patients who have been buying from "research use only" sellers a way into real clinical care, which is where a compliant brand earns trust.

What it does not change

It is not approval. Your website, ads and emails cannot call these peptides FDA approved, safe, or proven. It is not a marketing license. No healing, recovery, anti-aging or disease-treatment claims, and no before-and-after imagery. It is not permanent. Build your catalog so that if the policy changes, you update a product page instead of rebuilding a business. State rules still apply, and pharmacies and providers must be licensed where your patients live.

Critics and open questions

The move has critics. FDA staff had argued there was limited human data on these substances, and consumer-safety groups have publicly objected, with one filing a citizen petition asking the FDA to block compounding of these peptides. Founders should expect the conversation to continue, which is one more reason to keep claims conservative and documentation tight.

How to move first, the compliant way

1) Confirm with your pharmacy partner which of the six it is ready to compound, with certificates of analysis on file. 2) Have your providers build intake and protocols for each. 3) Update your formulary, product pages and consent language with accurate, claim-free copy. 4) Keep peptides as an extension of a diversified catalog, alongside hormone therapy, TRT, weight management and labs. 5) Re-check status on a schedule. GrowPro builds all of this with you, and existing GrowPro founders can add all six to the brand they already run.

Already a GrowPro founder? All six peptides can be added to the brand you run today. Talk to our team.

Frequently asked questions

Which peptides are covered by the HHS enforcement discretion?

Six: BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. These are the six the FDA Pharmacy Compounding Advisory Committee recommended in July 2026 for addition to the 503A bulks list.

Does enforcement discretion mean these peptides are FDA approved?

No. None of the six is an FDA-approved drug, and compounded medications are not FDA approved. Enforcement discretion only means regulators will not act against licensed pharmacies compounding them while rulemaking continues.

Is the peptide enforcement discretion permanent?

No. It is temporary while the FDA completes formal rulemaking, and it can be changed or withdrawn. Brands should plan for that possibility.

Can a telehealth brand now sell BPC-157?

A telehealth brand can offer it only through the prescribed model: a licensed provider evaluates each patient and, if appropriate, prescribes a preparation compounded by a licensed pharmacy. Selling research-use-only vials to consumers is still not telehealth and still carries enforcement risk.

When was the peptide enforcement discretion announced?

HHS announced it on October 28, 2026, and the notice was reported as scheduled for Federal Register publication on October 30, 2026.

Sources

This article is general education, not legal or medical advice. The six peptides named here are not FDA-approved drugs, and the HHS enforcement discretion is temporary and may change. Confirm current status with your pharmacy partner and healthcare counsel.